Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Novel and targeted cellular product causes cell death in non-Hodgkin lymphoma models

Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.

16 Dec 2019

UAB seminar on the extraordinary science of the immune system

"The human immune system makes my head explode," Pulitzer Prize-winning journalist Matt Richtel recently told a University of Alabama at Birmingham freshman seminar on immunology. "This is by far the hardest subject I have ever had to explore."

15 Dec 2019

NCCN Patient Advocacy Summit closes gaps in perspective of value in cancer care

The National Comprehensive Cancer Network (NCCN) hosted an annual NCCN Patient Advocacy Summit: Delivering Value for Patients across the Oncology Ecosystem in Washington, DC, today.

11 Dec 2019

Risk of specific genetic translocation is higher in patients of African ancestry, shows study

Multiple myeloma is a plasma cell cancer that is more common in patients of African American descent than of European American descent.

10 Dec 2019

Scientists highlight the benefits of Droplet Digital PCR technology at the 2019 ASH meeting

Scientists will present more than 40 abstracts highlighting research driven in part by Bio-Rad Laboratories' Droplet Digital PCR (ddPCR) technology at the 2019 American Society of Hematology (ASH) meeting in Orlando Florida, December 7-10.

10 Dec 2019

Combination therapy is safe and effective for older patients diagnosed with acute lymphoblastic leukemia

A study led by The University of Texas MD Anderson Cancer Center showed that treatment combining lower doses of chemotherapy with the monoclonal antibody inotuzumab ozogamicin (INO), with or without the drug blinatumomab, is safe and effective in patients over 60 years of age who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative ALL.

10 Dec 2019

Relapsed mantle cell lymphoma patients may benefit from CAR T-cell therapy

A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.

9 Dec 2019

Stem cell transplant following treatment with PD-1 inhibitor is safe, effective for patients with Hodgkin lymphoma

A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma, easing concerns that these patients are at heightened risk for severe immune-related complications.

9 Dec 2019

Next-generation sequencing can detect genetic alterations specific to follicular lymphoma

People with follicular lymphoma, a slow-growing lymphatic-system cancer, who have been treated and are in remission for at least two years, may no longer have what has been considered an incurable disease based on highly sensitive testing.

9 Dec 2019

$Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission$

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission.

8 Dec 2019

Researchers discover potent next generation of drugs to fight leukemia and lymphoma

UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of leukemia and lymphoma in adults and children.

6 Dec 2019

Cancer in the eye does not always develop into central nervous system lymphoma

Researchers at Okayama University report in the Journal of clinical and experimental hematopathology that primary intraocular lymphoma, a cancer in the eye, does not always develop into central nervous system lymphoma.

6 Dec 2019

New approach can improve the activity of CAR-T cells against blood and solid cancers

A new approach to programing cancer-fighting immune cells called CAR-T cells can prolong their activity and increase their effectiveness against human cancer cells grown in the laboratory and in mice, according to a study by researchers at the Stanford University School of Medicine.

5 Dec 2019

Young patients with IBD have increased risk of severe viral infections

Young patients with inflammatory bowel disease are five times more likely than the general population to develop viral infections that can lead to hospitalization or permanent organ damage, a new study published in the UEG Journal has found.

5 Dec 2019

A major step toward preventing GvHD in patients receiving bone marrow transplants

A drug used for rheumatoid arthritis has moved a step closer to FDA approval for a desperately needed new use.

4 Dec 2019

Study highlights the need to adhere to more uniform diagnostic criteria for rare lymphoma

In what is believed to be one of the largest studies of a rare disorder known as primary cutaneous gamma delta T-cell lymphoma, Rutgers Cancer Institute of New Jersey investigators and other collaborators examined characteristics, treatment patterns and outcomes of the disease, and determined accurate diagnosis of the disease requires ongoing analysis.

4 Dec 2019

Study: Calcium signaling can help address drug resistance to non-Hodgkin lymphoma

Gene expression profiling and other analyses conducted by Rutgers Cancer Institute of New Jersey researchers and colleagues examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma have identified calcium signaling as a novel and exploitable target in overcoming this treatment obstacle.

3 Dec 2019

Unexpected versatility of an ancient DNA repair factor revealed

If a bone breaks or a tendon snaps, you know to seek treatment immediately. But your most fragile and precious cellular commodity, chromosomal DNA, breaks with astounding frequency- some estimate as many as 10,000 times a day per cell- usually without consequence.

2 Dec 2019

UCLA scientists discover link between a protein and human blood stem cell self-renewal

UCLA scientists have discovered a link between a protein and the ability of human blood stem cells to self-renew. In a study published today in the journal Nature, the team reports that activating the protein causes blood stem cells to self-renew at least twelvefold in laboratory conditions.

27 Nov 2019

Cancer patients have higher risk of cardiovascular death

A new study says that over 10% of patients with cancer die of unrelated cardiovascular disease (CVD) rather than their cancers.

25 Nov 2019

Lymphoma News and Research

Further Reading

Novel and targeted cellular product causes cell death in non-Hodgkin lymphoma models

UAB seminar on the extraordinary science of the immune system

NCCN Patient Advocacy Summit closes gaps in perspective of value in cancer care

Risk of specific genetic translocation is higher in patients of African ancestry, shows study

Scientists highlight the benefits of Droplet Digital PCR technology at the 2019 ASH meeting

Combination therapy is safe and effective for older patients diagnosed with acute lymphoblastic leukemia

Relapsed mantle cell lymphoma patients may benefit from CAR T-cell therapy

Stem cell transplant following treatment with PD-1 inhibitor is safe, effective for patients with Hodgkin lymphoma

Next-generation sequencing can detect genetic alterations specific to follicular lymphoma

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

Researchers discover potent next generation of drugs to fight leukemia and lymphoma

Cancer in the eye does not always develop into central nervous system lymphoma

New approach can improve the activity of CAR-T cells against blood and solid cancers

Young patients with IBD have increased risk of severe viral infections

A major step toward preventing GvHD in patients receiving bone marrow transplants

Study highlights the need to adhere to more uniform diagnostic criteria for rare lymphoma

Study: Calcium signaling can help address drug resistance to non-Hodgkin lymphoma

Unexpected versatility of an ancient DNA repair factor revealed

UCLA scientists discover link between a protein and human blood stem cell self-renewal

Cancer patients have higher risk of cardiovascular death

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News